Feb 21,2018

Senseonics adds friends-and-family data sharing to CGM app in EMEA market

Implantable glucose sensor company Senseonics has launched a remote monitoring app for its users in Europe, the Middle East, and Africa, where its CGM system is distributed by Roche.

PRODUCT

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Feb 26,2018

FDA expands indication for MiniMed 670G's CGM to include upper arm

The FDA has expanded its indication for Medtronic’s Guardian Sensor 3, allowing patients to wear the sensor on their upper arm. The sensor is part of Medtronic’s MiniMed 670G system, and is currently the only continuous glucose monitor approved by the FDA to control automated insulin delivery via a hybrid closed loop system.

REGULATORY FDA

#cgm

#closed loop

View Analyst & Ambassador Comments
Go to original news
Feb 02,2018

The European Patent Office has granted Brighter's patent application

The European Patent Office has granted Brighter's patent application no. 14864054.3, regarding method and device for logging drug injections made by a medical device with injector.

PRODUCT

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Feb 06,2018

BD Announces Results For 2018 First Fiscal Quarter; Provides Fiscal 2018 Guidance Updated For Inclusion Of Bard

BD (Becton, Dickinson and Company), a leading global medical technology company, today reported quarterly revenues of $3.080 billion for the first fiscal quarter ended December 31, 2017. This represents an increase of 5.4 percent from the prior-year period, or 3.7 percent on a currency-neutral basis, and includes an estimated 110 basis point adverse impact from the previously disclosed change in the U.S. dispensing business model.

View Analyst & Ambassador Comments
Go to original news
Feb 07,2018

Virta Health’s Treatment for Sustained Type 2 Diabetes Reversal Provides New Hope for Chronic Disease Patients

Virta Health, the first company with a clinically-proven treatment to safely and sustainably reverse type 2 diabetes and other chronic metabolic diseases without the use of medications or surgery, today announced the peer-reviewed publication of 1-year results from its ongoing clinical trial, now 2.5 years in duration. The study augments Virta Health’s existing body of peer-reviewed research, which proved that the Virta Treatment could systematically reverse type 2 diabetes in as little as 10 weeks.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Feb 09,2018

Nemaura Medical Inc. Reports Third Quarter 2017 Financial Results

Nemaura Medical Inc., a medical technology company developing the wireless sugarBEAT® non-invasive glucose monitoring system for adjunctive use by persons with diabetes today reported financial results for the third quarter ended December 31, 2017. At December 31, 2017, the Company’s combined cash and bank fixed deposits was $6,453,745.

View Analyst & Ambassador Comments
Go to original news
Feb 13,2018

Medtronic Announces Upcoming Data Presentations at the Advanced Technologies and Treatments for Diabetes 11th International Conference

Medtronic plc, the global leader in medical technology, today announced its schedule of notable sessions that will be presented at the Advanced Technologies & Treatments for Diabetes (ATTD) 11th International Conference in Vienna, Austria, from February 14-17. A significant portion of the scientific data being presented focuses on the company's insulin pump systems, including new data on the benefits of the latest SmartGuard technology that drives the MiniMed 670G system1 in children with type 1 diabetes.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Feb 14,2018

Insulet Has Strong Presence at the International ATTD Congress; Presents Positive Study Results for Its Omnipod Horizon™ Hybrid Closed-Loop System

Insulet Corporation, the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced promising new data for its Omnipod Horizon™ Automated Glucose Control System (Omnipod Horizon) hybrid closed-loop system, which will be presented at the 11th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) congress in Vienna, Austria. Two studies demonstrated that the Omnipod Horizon algorithm performed well in response to meal challenges and exercise in 24 adults with type 1 diabetes. Results showed strong blood glucose control with time in target range (70-180 mg/dL or 3.9-10.0 mmol/L) of approximately 75% and 85% with real-life challenges including high-fat meals and moderate intensity exercise.

CLINICAL STUDY

#closed loop

View Analyst & Ambassador Comments
Go to original news
Feb 14,2018

Tandem Diabetes Care Schedules Fourth Quarter and Full Year 2017 Earnings Press Release and Conference Call

Tandem Diabetes Care®, Inc., a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, plans to release its fourth quarter and full year 2017 results after the financial markets close on Thursday, March 1, 2018.

View Analyst & Ambassador Comments
Go to original news
Feb 15,2018

Tandem Diabetes Care and Rubin Medical Announce Agreement for Distribution of Insulin Pump Products in Scandinavia

Tandem Diabetes Care®, Inc., a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced that it has entered into a distribution agreement with Rubin Medical to commercialize Tandem's t:slim X2™ Insulin Pump, insulin cartridges, and t:lock™ family of Infusion Sets in Sweden, Norway and Denmark.

PRODUCT

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES